Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose MenACWY vs MenC conjugate vaccine in 12-month-old toddlers
2013-000145-39Phase 3Suspended
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meningococcal A conjugate vaccine in meningococcal meningitis (2 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity: hSBA titers ≥8 for serogroups A, W, Y at Day 28. Started May 2013; status: suspended.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on 2013-000145-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000145-39.